- Spain CIMA (Spanish): search for “cinnarizina” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- Hypersensitivity
Dosing: Adult
- Motion sickness (adults): 30 mg 2 hours before travel, then 15 mg every 8 hours during the journey
- Motion sickness (children 5 to 12 years): Half the adult dose
Dosing: Altered kidney function
Cinnarizine is extensively metabolized by the liver (CYP2D6); metabolites are excreted about one-third in urine and two-thirds in feces. The Irish label has no kidney studies and advises using it with care in kidney insufficiency, without a dose change. It has no US FDA label.
Kidney function measure: The SmPC does not grade kidney impairment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Motion sickness: 30 mg 2 hours before travel, then 15 mg every 8 hours during the journey (SmPC).
- CrCl 30–59 mL/min
- No specific studies in kidney impairment; the SmPC says to use with care. Use with caution and specialist judgment.
- CrCl 15–29 mL/min
- No specific studies in kidney impairment; the SmPC says to use with care. Use with caution and specialist judgment.
- CrCl <15 mL/min (not on dialysis)
- No specific studies in kidney impairment; the SmPC says to use with care. Use with caution and specialist judgment.
- Hemodialysis (intermittent)
- Not studied in dialysis; no dose given.
- Peritoneal dialysis
- Not studied in dialysis; no dose given.
- CRRT
- Not studied in dialysis; no dose given.
- Dialyzable? Not stated (91% protein-bound).
- Monitoring Sedation (worse with alcohol and central nervous system depressants); extrapyramidal symptoms and parkinsonism, especially in older adults on long-term use (SmPC 4.4, 4.8).
Children (kidney dosing)
- eGFR ≥60
- No pediatric kidney data; use with care.
- eGFR 30–59
- No pediatric kidney data; use with care.
- eGFR 15–29
- No pediatric kidney data; use with care.
- eGFR <15 (not on dialysis)
- No pediatric kidney data; use with care.
- Hemodialysis (intermittent)
- No pediatric kidney data; use with care.
- Peritoneal dialysis
- No pediatric kidney data; use with care.
- CRRT
- No pediatric kidney data; use with care.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (March 2024). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Motion sickness: 5 to 12 years at half the adult dose (SmPC).
- Usual dose
- 5 to 12 years: half the adult dose.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Tablet: 25 mg
- Capsule: 75 mg
- Film-coated tablet: 25 mg
Registered products in the Philippines
26 products registered with the Food and Drug Administration (FDA) Philippines list Cinnarizine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products26
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CinnablocCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-5330 | Dec 13, 2029 | |
CinnablocCinnarizine | 75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-5317 | Dec 24, 2028 | |
CinnarexCinnarizine | 25 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Roymed PharmaceuticalTrader: Westfield Pharmaceuticals, Inc. | DRP-1367-03 | Feb 10, 2028 | |
CinnarigoCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3100-04 | Jul 5, 2029 | |
CinzitabCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-5500 | Sep 17, 2029 | |
Dizzinon ForteCinnarizine | 75 mg CapsuleAlu/Clear PVC Blister Pack of 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Justright Healthcare Inc. | DR-XY37385 | Jan 21, 2030 | |
EmecinCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3100 | Jul 5, 2029 | |
GalcinarCinnarizine | 25 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Beracah Pharma Phils., Inc.Trader: Foramen Products Corporation | DR-XY19388-B | Jul 17, 2027 | |
GorizineCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation | DRP-3100-03 | Jul 5, 2029 | |
LorizineCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | D & G PharmaImporter: Ambica International Corporation | DRP-3100-02 | Jul 5, 2029 | |
MoticonCinnarizine | 25 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-1367 | Feb 10, 2028 | |
NoneCinnarizine | 25 mg TabletAlu/PCTFE Blister Pack x 10's (Box of 30's) | Rx | UNILAB, INC.Philippines | Trader: RITEMED PHILS., INC. | DR-XY37211 | Dec 18, 2029 | |
NoneCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-3100-05 | Jul 5, 2029 | |
NoneCinnarizine | 25 mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-3967-01 | Mar 3, 2029 | |
NoneCinnarizine | 25 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Ritemed Phils., Inc. | DRP-9409 | Jul 15, 2028 | |
NoneCinnarizine | 75 mg CapsulePVC/PVTFE Alu Blister Pack (Box of 10's) | Rx | UNILAB, INC.Philippines | Trader: RITEMED PHILS., INC. | DR-XY38677 | Oct 20, 2030 | |
NoneCinnarizine | 75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Aldril Pharmaceuticals, Inc. | DRP-5317-02 | Dec 24, 2028 | |
RizineCinnarizine | 25 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals, Inc. | DRP-14464 | Sep 8, 2028 | |
StugeronCinnarizine | 25 mg TabletAlu/PVC Blister Pack x 20's (Box of 200's) | Rx | Janssen Korea Ltd.Republic of Korea | Zuellig Pharma CorporationImporter: Johnson & Johnson (Philippines), Inc. | DR-XY34825 | Aug 20, 2028 | |
StugeronCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 25's (Box of 200's) | Rx | Janssen Cilag S.p.A.Italy | Importer: Johnson & Johnson (Philippines), Inc. | DR-XY47759 | Feb 28, 2027 | |
Stugeron ForteCinnarizine | 75 mg CapsuleClear PVC-Alu Blister pack of 10's Box of 100’s | Rx | Janssen Korea Ltd.Republic of Korea | Zuellig Pharma CorporationImporter: Johnson & Johnson (Philippines), Inc. | DR-XY40786 | Mar 26, 2027 | |
SynazinCinnarizine | 75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100’s) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-635 | May 9, 2027 | |
VercinCinnarizine | 75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Lloyd Laboratories, Inc.Philippines | Totalcare Pharma Inc.Trader: Aldril Pharmaceuticals, Inc. | DRP-5317-01 | Dec 24, 2028 | |
VercureCinnarizine | 75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril International Co., Inc.Trader: Aldril Pharmaceuticals, Inc. | DRP-5317-03 | Dec 24, 2028 | |
VertexCinnarizine | 25 mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-3967 | Mar 3, 2029 | |
VertisinCinnarizine | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Yu Sheng Pharmaceutical Co., Ltd.Taiwan | Littman Drug Corporation | DR-XY25924 | Feb 9, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Alcohol, central nervous system depressants, tricyclic antidepressants | Adjust or monitor | More sedation. | Avoid alcohol; caution with depressants. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Somnolence (9.9%)
- Nausea (3.0%)
- Weight gain (1.5%)
Serious
- Extrapyramidal disorder, parkinsonism, dyskinesia
- Cholestatic jaundice
- Subacute cutaneous lupus erythematosus, lichen planus
Monitoring parameters
- Sedation (worse with alcohol and central nervous system depressants); extrapyramidal symptoms and parkinsonism, especially in older adults on long-term use (SmPC 4.4, 4.8). Kidney
- Sedation; extrapyramidal signs in older adults
Pharmacokinetics
Key PK parameters
| Time to peak | 2.5 to 4 hours |
|---|---|
| Half-life | 4 to 24 hours |
| Protein binding | 91% |
| Metabolism (CYP, transporters) | Extensive, mainly CYP2D6 |
| Renal excretion kidney | Metabolites about one-third in urine, two-thirds in feces |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Cinnarizine 25 mg Tablet | ₱0.65–₱1.50Reference ₱1.20 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Cinnarizine |
| PNF listing | Oral: 25 mg tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Stugeron 15 mg tablets SmPC (PA23490/024/001) [HPRA (Ireland) product information, March 2024; no US FDA label]. https://assets.hpra.ie/products/Human/22248/Licence_PA23490-024-001_01032024124558.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- JNTL Consumer Health I (Ireland) Limited. (2024). Stugeron 15 mg tablets (cinnarizine) [Summary of product characteristics, licence PA23490/024/001; text revised March 2024]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/22248/Licence_PA23490-024-001_01032024124558.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .